3TC30mg+AZT60mg disp. tabs/PAC-60

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Lamivudine 30mg + Zidovudine 60mg dispersible tablets, bottle pack of 60

Technical Specifications:
Each dispersible tablet contains Lamivudine 30mg and Zidovudine 60mg. Tablets are used to prepare an oral suspension.

Tablets should be scored with at least one break line to allow for division of tablets into two parts, each containing the same amount of active ingredient

Therapeutic class:
Nucleoside Reverse Transcriptase Inhibitors (NRTI)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


and

WHO Essential Medicines Library


or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

WHO HIV/AIDS


WHO Generic tool for assessing paediatric ARV dosing


Indications:
Management of HIV-1 infection in children and adults. Administration by mouth (oral), PO, as dispersible tablet for oral suspension

Storage
Do not store above 30°C (86°F)
Store in tightly closed original container
Protect from light.
Keep out of reach and sight of children.

Dispensing instructions:
Dispense in original container. Do not repack.
Tablets are to be dispersed in 5ml water immediately before administration

Regulatory status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines


List of USFDA approved and tentatively approved items